Changes in blood cell gene profile may impact leukemia outcomes
In people with acute myeloid leukemia (AML), changes in the gene profile of blood-forming stem cells, leading to a more youthful blood cell profile, could…
Andrea Lobo, — 
Articles by Andrea Lobo
Sarclisa under FDA priority review as first-line myeloma therapy
The U.S. Food and Drug Administration (FDA) has granted priority review to Sanofi’s application of Sarclisa (isatuximab) in combination with standard of care for…
Abecma OK’d in US to take earlier in treatments for multiple myeloma
The U.S. Food and Drug Administration (FDA) has expanded the indication of Abecma (idecabtagene vicleucel) to allow its use earlier in the therapy regimen…
CAR T-cell therapy recommended as earlier treatment line for RRMM
An advisory committee of the U.S. Food and Drug Administration (FDA) has unanimously recommended extending the approval of Janssen’s Carvykti (ciltacabtagene autoleucel) as an…
Phase 1b trial of STAR-LLD combo for myeloma approved by FDA
The U.S. Food and Drug Administration (FDA) has cleared the launch of a Phase 1b trial to test STAR-LLD, Starton Therapeutics’ experimental continuous delivery…